AccuStem Sciences Limited (ACMSY) Research
AccuStem Sciences Limited, founded in 2020 and headquartered in London, United Kingdom, focuses on providing diagnostic assays that utilize genomic signatures. These tests are developed to forecast the probability of both short-term and long-term relapse of ER+/HER2 breast cancer in individuals with an early-stage diagnosis.
Market snapshot
- Symbol
- ACMSY
- Price
- $0.13
- Day change
- -7.14%
- Market cap
- $2.0M
- P/E ratio
- -0.00x
- 52-week range
- 0.12-0.13
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
Recent insider activity
- CERRONE GABRIELE M — P-Purchase (400 shares) on 2025-06-13
- CERRONE GABRIELE M — P-Purchase (2000 shares) on 2025-06-13
- CERRONE GABRIELE M — P-Purchase (8991 shares) on 2025-06-12
- CERRONE GABRIELE M — P-Purchase (28205 shares) on 2025-06-11
- CERRONE GABRIELE M — P-Purchase (3000 shares) on 2025-04-09
Open AccuStem Sciences Limited (ACMSY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.